Menu Search
Equities

Enzo Biochem Inc

ENZ:NYQ

Enzo Biochem Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.15
  • Today's Change0.02 / 1.77%
  • Shares traded115.13k
  • 1 Year change-12.21%
  • Beta0.7469
Data delayed at least 15 minutes, as of Nov 09 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Enzo Biochem Inc had net income fall from a gain of 20.29m to a loss of 26.08m despite relatively flat revenues.
Gross margin45.86%
Net profit margin-30.77%
Operating margin-38.77%
Return on assets-9.46%
Return on equity-14.59%
Return on investment-13.74%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Enzo Biochem Inc fell by 31.00m. Cash Flow from Investing was negative at 545.00k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 26.26m for operations while cash used for financing totalled 4.19m.
Cash flow per share-0.1679
Price/Cash flow per share--
Book value per share1.07
Tangible book value per share1.07
More ▼

Balance sheet in USDView more

Enzo Biochem Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio2.82
Quick ratio2.55
Total debt/total equity0.0047
Total debt/total capital0.0047
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.